PTPA and cancer: Using fostriecin, a drug developed as a cancer therapy because it inhibited topoisomerase II, colleagues could present evidence in isolated perfused rabbit hearts that PP2A exerts detrimental cardiac effects in ischemia and reperfusion [45].